- organizations:Eyenovia
Pipeline
Eyenovia's phase 3 pediatric myopia trial fails primary goal
Company reports insignificant findings on drug-device combo of low-dose atropine and its Optejet system; announces next steps.
Products
Eyenovia launches clobetasol propionate suspension in US
Originally developed by Formosa, the solution is indicated to treat pain and inflammation following ocular surgery.
Products
Formosa to ship clobetasol propionate to US for commercialization
With exclusive rights owned by Eyenovia, the FDA-approved formulation is indicated to treat pain and inflammation following ocular surgery.
Pipeline
Eyenovia and Formosa to co-develop clobetasol propionate solution for DED
Partnership will feature FDA-approved eye drop and Optejet delivery system for precision dosing.
Pipeline
Eyenovia and SGN Nanopharma partner on nanoparticle-based cyclosporine for dry eye
Collaboration will integrate the Optejet topical dispenser with a unique cyclosporine formulation for a more effective treatment.
Pipeline
Eyenovia and Senju to develop chronic dry eye drop-device combo
Collaboration features the Optejet dosing delivery system delivering a corneal epithelial wound healing-ophthalmic solution.
Products
FDA approves clobetasol propionate suspension for postop inflammation and pain
Developed by Formosa with exclusive U.S rights owned by Eyenovia, the novel ophthalmic APP13007 is expected to launch mid-2024.
Pipeline
Eyenovia acquires US rights to Formosa's APP13007
Worth up to $86 million, the deal could also include payments following a potential FDA approval.
Products
FDA approves Eyenovia's Mydcombi for mydriasis
Approval is the first for a fixed-dose combination of tropicamide and phenylephrine in the U.S.
Pipeline
Eyenovia releases positive data on Optejet delivery system for glaucoma treatment
New study compares effectiveness of glaucoma medication administered via the company’s delivery system versus standard or conventional drops.
Archives
Can I have one dilation drop instead of two? — Weekly Glance
Maybe! The FDA just accepted a new NDA application.
Pipeline